Long-term safety study for people with myotonic dystrophy type 1
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This is a follow-up study for people with myotonic dystrophy type 1 who already received the study drug PGN-EDODM1 in an earlier trial. It lets you continue treatment and helps researchers learn more about long-term safety and effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already completed a previous study where you received PGN-EDODM1.
- Your blood test and other lab results at the screening visit should be within normal range or not worrisome to the study doctor.
- You cannot have taken any other experimental drug, device, or product (besides PGN-EDODM1) in the 30 days before starting this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called PGN-EDODM1 for people with myotonic dystrophy type 1 (DM1). The goal is to see if it can help reduce symptoms like muscle stiffness (myotonia).
This study is a long-term follow-up for people with myotonic dystrophy type 1. It aims to find better ways to measure how the disease progresses, which could help develop future treatments.
This study follows people with myotonic dystrophy type 1 (DM1) over time to learn more about how the disease progresses. It collects health information and samples to help improve care.
This study follows people with myotonic dystrophy (DM1 or DM2) for 2 years to learn more about the disease. You must already be in the DM-Scope registry and have certain medical records available.
This study measures physical and lab “health markers” in people with myotonic dystrophy type 1 (DM1) to better understand how the disease changes over time. Some participants may also have a muscle biopsy to study tissue differences.
This trial is testing a new drug called SRP-1003 for people with myotonic dystrophy type 1 (DM1) who developed symptoms after age 12. The goal is to see if it can reduce muscle problems like myotonia (difficulty relaxing muscles) and improve daily function.
Hear when a new Myotonic Dystrophy 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.